Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 4/20 | 0.47 |
| ▸ | PPARG | P37231 | 3/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.43 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.42 |
| ▸ | MDH1 | P40925 | 1/20 | 0.42 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5511246 | 0.87 | PARP1 (0.44) | ARPARP1CYP4F2CYP4A11 | |
| SCHEMBL22335931 | 0.87 | CYP4A11 (0.57) | ARPARP1CYP4F2CYP4A11SMYD3 | |
| SCHEMBL5510075 | 0.86 | PARP1 (0.45) | ARPARP1CYP4F2CYP4A11SMYD3 | |
| SCHEMBL5517940 | 0.86 | PARP1 (0.45) | ARPARP1CYP4F2CYP4A11SMYD3 | |
| SCHEMBL4871286 | 0.85 | CYP4A11 (0.54) | ARPARP1CYP4F2CYP4A11SMYD3 | |
| SCHEMBL10983487 | 0.84 | PPARA (0.54) | PPARAPPARGKAT8MAPTLNPEP | |
| SCHEMBL28019655 | 0.84 | PPARA (0.54) | PPARAPPARGKAT8MAPTLNPEP | |
| SCHEMBL1132805 | 0.84 | PPARA (0.54) | PPARAPPARGKAT8MAPTLNPEP | |
| SCHEMBL9096446 | 0.84 | PPARA (0.54) | PPARAPPARGKAT8MAPTLNPEP | |
| SCHEMBL5514986 | 0.83 | PARP1 (0.43) | ARPPARAPARP1CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
| CN-115066418-A | Carboxy derivatives with anti-inflammatory properties | 西特瑞治疗有限公司 | 2022-09-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | CPA2, RO60, C5AR1 | AR 3384/4885PPARA 1223/4885PPARG 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.